Literature DB >> 14988661

Lipocalin-type prostaglandin D synthase in urine in adriamycin-induced nephropathy of mice.

Takamasa Tsuchida1, Naomi Eguchi, Yutaka Eguchi, Atsushi Numabe, Hiroshi Nakajima, Hiroshi Oda, Kousuke Seiki, Rie Hakamada-Taguchi, Yoshihiro Urade, Yoshio Uehara.   

Abstract

BACKGROUND/AIMS: Lipocalin-type prostaglandin D synthase (L-PGDS), an enzyme converting prostaglandin H(2) to prostaglandin D(2), occurs particularly in the cardiovascular system. Urinary L-PGDS excretion is increased in diabetes prior to overt proteinuria, suggesting that it is a predictor of renal injury. In this study, we tested the hypothesis that L-PGDS excretion reflects renal injury in primary glomerular diseases using Adriamycin-induced nephropathy in mice.
METHODS: Twenty 6-week-old ICR female mice were intravenously given a dose of 25 mg Adriamycin/kg body weight through the tail vein. 24-hour urine was collected every day, and blood samples were obtained.
RESULTS: The mice developed significant albuminuria from day 3 onward (p < 0.05), which was followed by overt proteinuria from day 4 (p < 0.05). Histological examination revealed focal mesangial expansion with partial tubular atrophy. Urinary L-PGDS excretion significantly increased from day 1 onward (p < 0.05), and apparently preceded the increase in urinary albumin excretions. Either serum L-PGDS or creatinine levels were not changed by administration of Adriamycin. However, serum creatinine levels were inversely correlated to urinary L-PGDS excretions (r = -0.88, p < 0.05). Immunohistochemistry showed that L-PGDS occurred in the tubules, but not in the glomeruli in Adriamycin mice and L-PGDS mRNA paralleled urinary L-PGDS excretion.
CONCLUSION: Urinary L-PGDS excretion is increased in Adriamycin-induced nephropathy, and this precedes overt albuminuria. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14988661     DOI: 10.1159/000076407

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  4 in total

1.  PGD2-CRTH2 pathway promotes tubulointerstitial fibrosis.

Authors:  Hideyuki Ito; Xiaoxiang Yan; Nanae Nagata; Kosuke Aritake; Yoshinori Katsumata; Tomohiro Matsuhashi; Masataka Nakamura; Hiroyuki Hirai; Yoshihiro Urade; Koichiro Asano; Masato Kubo; Yasunori Utsunomiya; Tatsuo Hosoya; Keiichi Fukuda; Motoaki Sano
Journal:  J Am Soc Nephrol       Date:  2012-09-20       Impact factor: 10.121

Review 2.  Biomarkers of systemic lupus erythematosus identified using mass spectrometry-based proteomics: a systematic review.

Authors:  Orthodoxia Nicolaou; Andreas Kousios; Andreas Hadjisavvas; Bernard Lauwerys; Kleitos Sokratous; Kyriacos Kyriacou
Journal:  J Cell Mol Med       Date:  2016-11-23       Impact factor: 5.310

Review 3.  The therapeutic potential of CRTH2/DP2 beyond allergy and asthma.

Authors:  Katharina Jandl; Akos Heinemann
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-08-14       Impact factor: 3.072

Review 4.  Prostaglandins in the pathogenesis of kidney diseases.

Authors:  Yuanyuan Li; Weiwei Xia; Fei Zhao; Zhaoying Wen; Aihua Zhang; Songming Huang; Zhanjun Jia; Yue Zhang
Journal:  Oncotarget       Date:  2018-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.